Article
Age-related changes in bone morphology are accelerated in group VIA phospholipase A2 (iPLA2beta)-null mice.
Washington University School of Medicine, Department of Internal Medicine, 660 S. Euclid Avenue, St. Louis, MO 63110, USA.
American Journal Of Pathology (impact factor:
4.89).
05/2008;
172(4):868-81.
DOI:10.2353/ajpath.2008.070756
pp.868-81
Source: PubMed
-
Citations (0)
- Cited In (1)
-
Article: Establishment of an improved mouse model for infantile neuroaxonal dystrophy that shows early disease onset and bears a point mutation in Pla2g6.
[show abstract] [hide abstract]
ABSTRACT: Calcium-independent group VIA phospholipase A(2) (iPLA(2)beta), encoded by PLA2G6, has been shown to be involved in various physiological and pathological processes, including immunity, cell death, and cell membrane homeostasis. Mutations in the PLA2G6 gene have been recently identified in patients with infantile neuroaxonal dystrophy (INAD). Subsequently, it was reported that similar neurological impairment occurs in gene-targeted mice with a null mutation of iPLA(2)beta, whose disease onset became apparent approximately 1 to 2 years after birth. Here, we report the establishment of an improved mouse model for INAD that bears a point mutation in the ankyrin repeat domain of Pla2g6 generated by N-ethyl-N-nitrosourea mutagenesis. These mutant mice developed severe motor dysfunction, including abnormal gait and poor performance in the hanging grip test, as early as 7 to 8 weeks of age, in a manner following Mendelian law. Neuropathological examination revealed widespread formation of spheroids containing tubulovesicular membranes similar to human INAD. Molecular and biochemical analysis revealed that the mutant mice expressed Pla2g6 mRNA and protein, but the mutated Pla2g6 protein had no glycerophospholipid-catalyzing enzyme activity. Because of the significantly early onset of the disease, this mouse mutant (Pla2g6-inad) could be highly useful for further studies of pathogenesis and experimental interventions in INAD and neurodegeneration.American Journal Of Pathology 11/2009; 175(6):2257-63. · 4.89 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
age-related losses
bone formation
bone marrow fat
bone mineralizing surfaces
bone strength
bones
cell origin
Cortical bone size
iPLA(2)beta causes abnormalities
iPLA(2)beta-null mice
KO mice
lower bone mass phenotype
osteoblast density
Phospholipases A(2)
signaling events
sn-2 fatty acid substituent
trabecular bone volume
undifferentiated bone marrow stromal cells
unrecognized role
WT mice